ArcticZymes Technologies - M&A Activity 2020

ArcticZymes Technologies announces closing of Biotec BetaGlucans divestment

Tromsø, Norway, 31. December 2020. With reference to announcement made on 14.

December 2020, ArcticZymes Technologies ASA (AZT) announces closing of the

Biotec BetaGlucans AS divestment.

Under the terms of the share purchase agreement (SPA) signed between ArcticZymes

Technologies ASA and Lallemand Inc's subsidiary, Danstar Ferment AG, all closing

conditions are fulfilled. In line with the SPA, ArcticZymes Technologies has

today received a consideration of NOK 70 million on a cash free, debt-free

basis. Closing of customary accounts adjustments will be completed when annual

figures are finalised.

For more information, please contact:

ArcticZymes Technologies

Børge Sørvoll, CFO

Tel: +47 95 29 01 87

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]

ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies

in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at

the SIVA Innovation Centre. ArcticZymes Technologies' unique IP and capabilities

are protected via a large portfolio of patents. For more information, please

visit the website: www.arcticzymes.com

AI assistant